Scar - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2017, provides an overview of the Scar (Dermatology) pipeline landscape.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Scar - Overview
Scar - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Scar - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Scar - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Albireo Pharma Inc
Altacor Ltd
Beech Tree Labs Inc
BirchBioMed Inc
BLR Bio LLC
Clanotech AB
Escape Therapeutics Inc
FirstString Research Inc
Kringle Pharma Inc
Moerae Matrix Inc
Pharmaxis Ltd
Promore Pharma
RXi Pharmaceuticals Corp
Synedgen Inc
VBS Pharmaceuticals
Scar - Drug Profiles
A-3914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-5425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLT-28643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FibroStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Fibrotic Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-34240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lysyl Oxidase for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics
Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting
Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO
Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference
Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Scar, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Scar - Pipeline by 3M Drug Delivery Systems, H1 2017
Scar - Pipeline by Albireo Pharma Inc, H1 2017
Scar - Pipeline by Altacor Ltd, H1 2017
Scar - Pipeline by Beech Tree Labs Inc, H1 2017
Scar - Pipeline by BirchBioMed Inc, H1 2017
Scar - Pipeline by BLR Bio LLC, H1 2017
Scar - Pipeline by Clanotech AB, H1 2017
Scar - Pipeline by Escape Therapeutics Inc, H1 2017
Scar - Pipeline by FirstString Research Inc, H1 2017
Scar - Pipeline by Kringle Pharma Inc, H1 2017
Scar - Pipeline by Moerae Matrix Inc, H1 2017
Scar - Pipeline by Pharmaxis Ltd, H1 2017
Scar - Pipeline by Promore Pharma, H1 2017
Scar - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Scar - Pipeline by Synedgen Inc, H1 2017
Scar - Pipeline by VBS Pharmaceuticals, H1 2017
Scar - Dormant Projects, H1 2017
Scar - Discontinued Products, H1 2017